Tonix Pharmaceuticals Holding Corp.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TNXP in the last 30 days.
See all $TNXP insider activity →Pfizer, Moderna, and others are developing Lyme disease treatments, including vaccines and drugs. Pfizer-Valneva's vaccine showed 73% efficacy in trials, with EU review underway. Tonix and Tarsus are working on preventive measures. Lyme cases have surged, with 476,000 annual diagnoses in the U.S. according to the CDC.
Tonix Pharmaceuticals (TNXP) announced a Medicare payer agreement for TONMYA, expanding coverage to 21 million more lives, totaling 32 million. The FDA approved TONMYA for fibromyalgia in 2025. However, individual plan formularies will determine patient copays, with factors like tier placement and prior authorization affecting costs. Medicare's out-of-pocket cap for 2027 is $2,400. Patients should use Medicare's Plan Finder to compare costs during open enrollment.
Tonix Pharmaceuticals (TNXP) announced it will present its TNX-801 vaccine platform at the World Vaccine Congress Europe 2026. TNX-801 is in preclinical development for mpox, smallpox, and other diseases, with a Phase 1 study expected in 2027. The company's shares rose 4.40% to $6.40.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TNXP (Tonix Pharmaceuticals Holding Corp.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent TNXP coverage spans financial news, regulation and technology.
Early development stage; trial not yet started.
The agreement may boost Tonix's market visibility and sales potential but actual pricing impact depends on plan formularies.
The new Phase 1 timeline signals progress in the pre‑clinical program and may lift sentiment.
Preliminary numbers may prompt investors to adjust valuation.
The new facility signals long‑term growth investment, which may modestly boost the stock as investors price in expanded capacity.
AlphAI scores every news story that mentions TNXP with an AI model for sentiment and relevance, and aggregates insider trades from Tonix Pharmaceuticals Holding Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pfizer, Moderna, and others are developing Lyme disease treatments, including vaccines and drugs. Pfizer-Valneva's vaccine showed 73% efficacy in trials, with EU review underway. Tonix and Tarsus are working on preventive measures. Lyme cases have surged, with 476,000 annual diagnoses in the U.S. according to the CDC.
3 min readTonix Pharmaceuticals (TNXP) announced a Medicare payer agreement for TONMYA, expanding coverage to 21 million more lives, totaling 32 million. The FDA approved TONMYA for fibromyalgia in 2025. However, individual plan formularies will determine patient copays, with factors like tier placement and prior authorization affecting costs. Medicare's out-of-pocket cap for 2027 is $2,400. Patients should use Medicare's Plan Finder to compare costs during open enrollment.
2 min readTonix Pharmaceuticals (TNXP) announced it will present its TNX-801 vaccine platform at the World Vaccine Congress Europe 2026. TNX-801 is in preclinical development for mpox, smallpox, and other diseases, with a Phase 1 study expected in 2027. The company's shares rose 4.40% to $6.40.
2 min readTonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended September 30, 2026. For the three months ended September 30, 2026, the Company’s net revenue for
2 min readTonix Pharmaceuticals began construction on a 44-acre facility in Hamilton, Montana, to produce TNX 4800, a Lyme disease prophylactic. The project, expected to take several years, aims to boost local biotech infrastructure and economic development. Local leaders and former U.S. Senator Max Baucus highlighted the company's patient-centered approach and potential impact on Montana's biotech sector.
1 min readTonix Pharmaceuticals (TNXP) received a Paragraph IV notice from Dr. Reddy’s for a generic version of TONMYA. Dr. Reddy’s challenged four patents in an ANDA filing, triggering a 45-day window for Tonix to sue. Tonix plans to enforce its IP but cannot predict litigation outcomes or generic entry timing.
1 min readTonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 1, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) received a notice (the “Notice”) from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”) stating that DRL filed an Abbreviated New Drug Application
1 min readTonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Other Events. Exhibit 99.01 Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA ® New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer
2 min readTonix Pharmaceuticals (TNXP) is targeting growth for its fibromyalgia drug, TONMYA, by focusing on prescribers with a history of diagnosing the condition. The company plans to start a Phase II trial for its Lyme disease prevention candidate, TNX-4800, early next year. Tonix had $176 million in cash and no debt at the end of Q2, with a cash runway into Q2 2027.
2 min readLEDERMAN SETH (Chief Executive Officer) purchased 2,000 indirectly-held shares of Tonix Pharmaceuticals Holding Corp. (TNXP) at $13.79 on 2026-08-27.
1 min read
